Skip to content
value.today
FATE Therapeutics Inc. logo

FATE Therapeutics Inc.

Total raised
$45 M
2 rounds on record
Latest round
$9 M
May 2012
First round on record
Nov 2009
Today
Went public
See the company page

FATE Therapeutics Inc. is listed today as Fate Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding, 5 other private sales on record. Open the number of investors for the round's details.

Funding rounds of FATE Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2020$50 MPrivate placement after listing$50 to $250 million

FATE Therapeutics Inc.: Private sale, Jun 2020

Investors in this round

1 investor had bought by the notice of Jul 6, 2020: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for FATE Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$50 M of $50 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Cindy Tahl · Executive Officer
  • J. Scott Wolchko · Executive Officer, Director
  • John Mendlein · Director
  • Karin Jooss · Director
  • Michael Lee · Director
  • Robert Epstein · Director
  • Robert Hershberg · Director
  • Shefali Agarwal · Director
  • Timothy Coughlin · Director
  • William Rastetter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by J. Scott Wolchko, Chief Executive Officer and President. Source: SEC Form D, newest notice filed Jul 6, 2020. Read the notice at the SEC.

equitySEC
Apr 2020$50 MPrivate placement after listing$50 to $250 million

FATE Therapeutics Inc.: Private sale, Apr 2020

Investors in this round

1 investor had bought by the notice of Apr 21, 2020: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for FATE Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$50 M of $50 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Cindy Tahl · Executive Officer
  • J. Scott Wolchko · Executive Officer, Director
  • Amir Nashat · Director
  • John Mendlein · Director
  • Karin Jooss · Director
  • Michael Lee · Director
  • Robert Epstein · Director
  • Shefali Agarwal · Director
  • Timothy Coughlin · Director
  • William Rastetter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by J. Scott Wolchko, Chief Executive Officer and President. Source: SEC Form D, newest notice filed Apr 21, 2020. Read the notice at the SEC.

equitySEC
Nov 2016$57 MPrivate placement after listing$50 to $250 million

FATE Therapeutics Inc.: Private sale, Nov 2016

Investors in this round

21 investors had bought by the notice of Dec 8, 2016: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for FATE Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$57 M of $57 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,664,999
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Chris D. Storgard · Executive Officer
  • Cindy D. Tahl · Executive Officer
  • Daniel D. Shoemaker · Executive Officer
  • J. Scott Wolchko · Executive Officer, Director
  • Stewart S. Abbot · Executive Officer
  • Amir S. Nashat · Director
  • John S. Mendlein · Director
  • Mark J. Enyedy · Director
  • Robert S. Epstein · Director
  • Timothy P. Coughlin · Director
  • William S. Rastetter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • LEERINK PARTNERS LLC (CRD 39011) · Boston, MassachusettsSold in all US states

Signed by J. Scott Wolchko, President and chief executive officer. Source: SEC Form D, newest notice filed Dec 8, 2016. Read the notice at the SEC.

equitySEC
Aug 2016$10 MPrivate placement after listing$10 to $50 million

FATE Therapeutics Inc.: Private sale, Aug 2016

Investors in this round

4 investors had bought by the notice of Aug 19, 2016: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for FATE Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Chris D. Storgard · Executive Officer
  • Cindy D. Tahl · Executive Officer
  • Daniel D. Shoemaker · Executive Officer
  • J. Scott Wolchko · Executive Officer, Director
  • Stewart S. Abbot · Executive Officer
  • Amir S. Nashat · Director
  • John S. Mendlein · Director
  • Mark J. Enyedy · Director
  • Robert S. Epstein · Director
  • Timothy P. Coughlin · Director
  • William S. Rastetter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by J. Scott Wolchko, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 19, 2016. Read the notice at the SEC.

equitySEC
May 2015$8 MPrivate placement after listing$2 to $10 million

FATE Therapeutics Inc.: Private sale, May 2015

Investors in this round

1 investor had bought by the notice of May 18, 2015: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for FATE Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christian Weyer · Executive Officer, Director
  • Daniel Shoemaker · Executive Officer
  • J. Scott Wolchko · Executive Officer
  • Amir Nashat · Director
  • John Mendlein · Director
  • Mark Enyedy · Director
  • Robert Epstein · Director
  • Timothy Coughlin · Director
  • William Rastetter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by J. Scott Wolchko, Chief financial officer. Source: SEC Form D, newest notice filed May 18, 2015. Read the notice at the SEC.

equitySEC
May 2012$9 MNo. 2$2 to $10 million

FATE Therapeutics Inc.: Raise no. 2, May 2012

Investors in this round

17 investors had bought by the notice of Aug 21, 2012: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for FATE Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$9 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Scott Wolchko · Executive Officer
  • William T. Rastetter · Executive Officer, Director
  • Amir Nashat · Director
  • Bryan E. Roberts · Director
  • Carl Weissman · Director
  • John Mendlein · Director
  • Mark T. Enyedy · Director
  • Robert T. Nelsen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Scott Wolchko, Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 21, 2012. Read the notice at the SEC.

equitySEC
Nov 2009$36 MNo. 1$10 to $50 million

FATE Therapeutics Inc.: Raise no. 1, Nov 2009

Investors in this round

18 investors had bought by the notice of Apr 20, 2011: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for FATE Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$36 M of $36 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel T. Shoemaker · Executive Officer
  • John Mendlein · Executive Officer, Director
  • Scott Wolchko · Executive Officer
  • Amir Nashat · Director
  • Bryan E. Roberts · Director
  • Carl Weissman · Director
  • Robert T. Nelsen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Scott Wolchko, Chief Financial Officer. Source: SEC Form D and 2 amendments, newest notice filed Apr 20, 2011. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • FATE Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2020).

    SEC Form D · Jul 2020

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2020

That is all the official record says: FATE Therapeutics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of FATE Therapeutics Inc. are on record.

Investors#

18 named in official filings. Open an investor to see everything it has backed.

Investors in FATE Therapeutics Inc.
InvestorKindAmountRoundRoleSource
Arch Venture Fund VI LPVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Arch Venture Partners VI LLCVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Arch Venture Partners VI LPVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Ovp Venture Partners VII LPVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Ovp VII Entrepreneurs Fund LPFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Polaris Venture Management Co. V, L.L.C.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Polaris Venture Partners Entrepreneurs' Fund V, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Polaris Venture Partners Founders' Fund V, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Polaris Venture Partners Special Founders' Fund V, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Polaris Venture Partners V, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
RedCo II Master Fund, L.P.Fund or asset managernot statednot statedHeld preferred stock, 10% owner, director (Form 3, 2025)SEC Form 3
Redmile Group, LLCFund or asset managernot statednot statedHeld preferred stock, 10% owner, director (Form 3, 2018)SEC Form 3
VEF Management V, LLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Venrock Associates V LPFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Venrock Entrepreneurs Fund V, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Venrock Management V, LLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Venrock Partners Management V, LLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Venrock Partners V L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 18 investors.

Largest shareholders today

Institutions holding Fate Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by FATE Therapeutics Inc.
NameRoleNamed in
Cindy TahlExecutive officerJul 2020
J. Scott WolchkoExecutive officerJul 2020
Chris D. StorgardExecutive officerDec 2016
Cindy D. TahlExecutive officerDec 2016
Daniel D. ShoemakerExecutive officerDec 2016
Stewart S. AbbotExecutive officerDec 2016
Christian WeyerExecutive officerMay 2015
Daniel ShoemakerExecutive officerMay 2015
Scott WolchkoExecutive officerAug 2012
William T. RastetterExecutive officerAug 2012
Daniel T. ShoemakerExecutive officerApr 2011
John MendleinExecutive officerApr 2011
PAUL GraysonExecutive officerDec 2009
J. Scott WolchkoDirectorJul 2020
John MendleinDirectorJul 2020
Karin JoossDirectorJul 2020
Michael LeeDirectorJul 2020
Robert EpsteinDirectorJul 2020
Robert HershbergDirectorJul 2020
Shefali AgarwalDirectorJul 2020
Timothy CoughlinDirectorJul 2020
William RastetterDirectorJul 2020
Amir NashatDirectorApr 2020
Amir S. NashatDirectorDec 2016
John S. MendleinDirectorDec 2016
Mark J. EnyedyDirectorDec 2016
Robert S. EpsteinDirectorDec 2016
Timothy P. CoughlinDirectorDec 2016
William S. RastetterDirectorDec 2016
Christian WeyerDirectorMay 2015
Mark EnyedyDirectorMay 2015
Bryan E. RobertsDirectorAug 2012
Carl WeissmanDirectorAug 2012
Mark T. EnyedyDirectorAug 2012
Robert T. NelsenDirectorAug 2012
William T. RastetterDirectorAug 2012
PAUL GraysonDirectorDec 2009

About

A clinical-stage biopharmaceutical company in San Diego, United States.

Went public since 2013. Its SEC number is that of a company listed on a stock exchange.